Cardiac Sarcoidosis with LVEF Below 50% After Prednisone Failed to Stabilise Ejection Fraction

Clinical Scenario

This protocol applies to patients with sarcoidosis who have cardiac sarcoidosis and a left ventricular ejection fraction (LVEF) below 50%, and who did not achieve a stable or improved LVEF on the preceding treatment course.

Previous Treatment — Goal Not Met

The prior regimen — Prednisone — did not achieve the target of a stable or improved left ventricular ejection fraction. This protocol defines the next clinical step after that failure.

Next-Line Approach (Partial Preview)

In this situation, a steroid-sparing cytotoxic agent is considered as the next intervention. The specific selection and full regimen details are available in the complete structured protocol.

Agent choice, sequencing criteria, and all regimen specifics are behind the link below.

Instant Access to Structured Evidence-Based Regimens

References

Cytotoxic drugs are often used as steroid-sparing agents in patients with left ventricular ejection fraction (LVEF) <50% who require prednisone >10 mg/day for stable cardiac function.

View source ↗